Dörr, Tamara
Güsewell, Sabine
Flury, Domenica
Süveges, Maria
Gaza Valera, Camille Beatrice
Botero-Mesa, Sara
Zanella, Marie-Céline
Iten, Anne
Balmelli, Carlo
Troillet, Nicolas
Tschudin-Sutter, Sarah
W Schreiber, Peter
Jent, Philipp
Damonti, Lauro
Sommerstein, Rami
Portmann, Lea
Vuichard-Gysin, Danielle
Cusini, Alexia
Nussbaumer-Ochsner, Yvonne
Heininger, Ulrich
Berger, Christoph
Zimmermann, Petra
Gardiol, Céline
Keiser, Olivia
Schlegel, Matthias
Kohler, Philipp
P Kuster, Stefan
Funding for this research was provided by:
Schweizerische Akademie der Medizinischen Wissenschaften (YTCR 12/22)
Article History
Received: 6 February 2024
Accepted: 5 June 2024
First Online: 18 June 2024
Declarations
:
: The CH-SUR project was submitted and approved by the Geneva Ethics Committee (CCER) and by all hospitals’ local Ethics Committee through the Swissethics Business Administration System for Ethics Committees (BASEC) submission system, under reference 2020 − 00827 (COVID-19) and 2018 − 00577 (Influenza).
: Not applicable.
: P.W.S. received travel grants from Pfizer and Gilead, honoraria as a speaker and advisory board member from Pfizer, and honoraria from Gilead as an advisory board member outside of the submitted work. U.H. is a member of the Meta Data Safety Monitoring Board for CEPI (Coalition for Epidemic Preparedness Innovations). S. T.-S. and R. S. are active as Editors of Antimicrobial Resistance & Infection Control. The other authors report no conflicts of interest.